2 results
Approved WMOPrematurely terminated
To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with `standard' management by CTPA alone in a…
Approved WMORecruitment started
In the RAINBO POLEmut-BLUE trial, omission of adjuvant therapy will be investigated in very low risk disease and de-escalation of treatment (observation or radiotherapy, but not chemoradiation) in low risk disease.